SAN FRANCISCO, Nov. 7 – Paradigm Genetics on Wednesday posted third-quarter revenues of $6.3 million versus $3.5 for the same quarter a year ago, the company announced.

The Research Triangle Park, N.C.-based company attributed the revenue rise to output related to partnerships with Bayer and Monsanto.

Total operating expenses for the period increased 31 percent to $10.2 million from $7.8 million for the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.